3T Biosciences Strengthens Leadership with Key Appointments to Advance Solid Tumor Immunotherapy Pipeline
核心洞察
3T Biosciences (搜索) appointed Behzad Kharabi, M.D., as chief medical officer, bringing extensive experience from leading the development of CD19 (搜索) CAR-T therapy TECARTUS® for blood cancers (搜索).
Karen E. Knudsen, MBA, Ph.D., CEO of the Parker Institute for Cancer Immunotherapy, joined the company's board of directors to provide strategic guidance.
The appointments strengthen 3T's capabilities as it advances bispecific T-cell engager therapeutics targeting solid tumors (搜索), addressing unmet medical needs in immuno-oncology.
3T Biosciences (搜索), an immunotherapy company focused on solid tumors (搜索) and immune-mediated diseases, announced two key leadership appointments to strengthen its clinical development capabilities and strategic direction. The company named Behzad Kharabi, M.D., as chief medical officer and appointed Karen E. Knudsen, MBA, Ph.D., CEO of the Parker Institute for Cancer Immunotherapy (PICI), to its board of directors.
The appointments come as 3T advances its pipeline of bispecific T-cell engager (TCE) therapeutics for solid tumors (搜索), bringing together extensive clinical development experience and translational oncology expertise to guide the company's programs into clinical trials.
Proven Track Record in Cell Therapy Development
Dr. Kharabi brings significant experience in cell and gene therapy development, having led the global development of CD19 (搜索) CAR-T therapy TECARTUS®, which received approval for treating certain blood cancers (搜索). His appointment as chief medical officer positions 3T to leverage this proven track record as the company prepares to advance its bispecific T-cell engager programs into clinical development.
"Behzad has led global development programs for some of the most impactful cell therapies in our field, including the approval of TECARTUS® for the treatment of certain blood cancers (搜索)," said Stefan Scherer, M.D., Ph.D., CEO of 3T Biosciences (搜索).
Strategic Board Addition
Dr. Knudsen's appointment to the board brings deep translational oncology insight from her leadership role at PICI, where she oversees more than 100 immunotherapy studies. Her experience across the oncology ecosystem is expected to help shape 3T's scientific and clinical strategy as the company expands its pipeline.
"Karen's leadership at PICI and across the oncology ecosystem brings an invaluable perspective to our board," Dr. Scherer noted. "Her insight will help guide our strategy as we expand our pipeline and advance differentiated TCE candidates."
Addressing Solid Tumor Challenges
Both leaders emphasized the significant opportunity in developing TCE therapies for solid tumors (搜索), an area where existing immunotherapy approaches have shown limited success. Dr. Kharabi highlighted the company's approach to discovering novel T-cell receptor (搜索) (TCR) targets with enhanced specificity.
"TCE therapies represent one of the most promising frontiers in immuno-oncology, particularly for solid tumors (搜索) where existing approaches have fallen short," Dr. Kharabi said. "What stands out at 3T, is the ability to discover and validate truly novel, druggable T-cell receptor (搜索) (TCR) targets with a level of specificity we haven't seen before. This opens the door to therapies with greater potency and safety, and I'm eager to help bring these innovations to patients."
Dr. Knudsen echoed this sentiment, noting the compelling science behind 3T's approach. "3T is tackling one of the toughest challenges in immuno-oncology: delivering potent, selective TCR therapies for solid tumors (搜索)," she said. "The science is compelling, and the opportunity for patient impact is significant. I'm pleased to support the team as they move these programs forward."
The leadership appointments position 3T Biosciences (搜索) to advance its differentiated approach to solid tumor immunotherapy, combining novel target discovery with proven clinical development expertise as the company prepares to enter clinical trials with its bispecific T-cell engager therapeutics.